Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye
Aslı Bozdemir, Sibel Hacıoğlu, Gülsüm Akgün Çağlıyan, Nevin Alayvaz Aslan, Süleyman Utku Uzun, Kayıhan Kara, Utku Iltar, Orhan Kemal Yücel, Ünal Ataş, Selin Arslan Kirezli, Ali İhsan Gemici, İnci Alacacıoğlu, Mustafa Kemal Yeniay, Oktay Bilgir, Zehra Narlı Özdemir, Handan Haydaroğlu Şahin, Ayşe Uysa · 2026
Read Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye by Aslı Bozdemir, Sibel Hacıoğlu, Gülsüm Akgün Çağlıyan, Nevin Alayvaz Aslan, Süleyman Utku Uzun, Kayıhan Kara, Utku Iltar, Orhan Kemal Yücel, Ünal Ataş, Selin Arslan Kirezli, Ali İhsan Gemici, İnci Alacacıoğlu, Mustafa Kemal Yeniay, Oktay Bilgir, Zehra Narlı Özdemir, Handan Haydaroğlu Şahin, Ayşe Uysa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13513165.txt.
Description
Background: Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complications, and supportive care practices associated with relapsed/refractory multiple myeloma (RRMM).
Catalog record
| CREATOR | Aslı Bozdemir, Sibel Hacıoğlu, Gülsüm Akgün Çağlıyan, Nevin Alayvaz Aslan, Süleyman Utku Uzun, Kayıhan Kara, Utku Iltar, Orhan Kemal Yücel, Ünal Ataş, Selin Arslan Kirezli, Ali İhsan Gemici, İnci Alacacıoğlu, Mustafa Kemal Yeniay, Oktay Bilgir, Zehra Narlı Özdemir, Handan Haydaroğlu Şahin, Ayşe Uysa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |